Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27875)	2/5/1999 3:55:00 PM
From: WTDEC	Respond to of 32384

Panretin> (alitretinoin) Gel, 0.1%, Rx Ligand Pharmaceuticals NDA 20-886 2/2/99 Henry, it is indeed a long URL, but it is worth the trip>) Walter

To: Henry Niman who wrote (27875)	2/5/1999 6:37:00 PM
From: Cheryl Galt	Respond to of 32384

Henry, that long URL was a GREAT link. WOW what collection of timely information. On the line for panretin Gel, CLICK both (blue) dates at the right of the screen, and you'll see everything you want to know about how the FDA is handling the drug's NDA. The first one links to the 3-page approval letter, with reference to the Phase 4 study (which -- to me -- sounds worthwhile and interesting). The second links to 7 pages that I've not yet read, details about the labeling issues, ...... (Both are in Acrobat format, easily printed, but not available for cut and paste. ) Regards, Cheryl (information junkie)